Xconomy National

Archives

by in

Entry	Author	Date	Location
Fate Therapeutics Names Biotech Vet Bill Rastetter as Chairman, Interim CEO	Luke Timmerman	12/14/11	San Diego
Harvard Bioscience Tool Used in First Transplants of Synthetic Tracheae	Arlene Weintraub	12/01/11	Boston
AlloCure Stem Cell Trial Provides Glimpse of Promising Treatment for Kidney Damage	Arlene Weintraub	11/18/11	Boston
Geron Dumps Stem Cell R&D Programs, Axes 38% of Workforce	Luke Timmerman	11/14/11	San Francisco
Tolerx Shutters, Courtagen Gets $8M, OvaScience Emerges, & More Boston-Area Life Sciences News	Erin Kutz	10/14/11	Boston
Amgen Mulls R&D Cuts, Thong Le Named WBBA Chairman, NanoString’s Version 2.0, & More Seattle-Area Life Sciences News	Luke Timmerman	10/13/11	Seattle
Stem Cell Therapy: A Process With a Promise	Drew McUsic	10/10/11	Seattle
Geron Names Chip Scarlett, Former Proteolix, Tercica Boss, as New CEO	Luke Timmerman	09/30/11	San Francisco
Excerpt from “The Body Politic: The Battle Over Science in America”	Jonathan Moreno	09/29/11	National
Ipierian Hires New CEO to Carry on With Stem Cells for Discovering Neurological Drugs	Luke Timmerman	09/07/11	San Francisco
Thane Kreiner, the Biotech-Entrepreneur-Turned-Educator With 1 Billion People on His Mind	Luke Timmerman	08/25/11	San Francisco
Time to Cure Cancer or Stash Cash Under the Mattress?	Luke Timmerman	08/15/11	National
Advanced Cell Technology Starts Human Trials of Embryonic Stem Cells Under Strict FDA Supervision	Arlene Weintraub	07/20/11	Boston
SeaGen’s Big Day at the FDA, Hutch Nabs $20M HIV Grant, Allozyne’s Nasdaq Plan, & More Seattle-Area Life Sciences News	Luke Timmerman	07/14/11	Seattle
Fate Therapeutics Trims Chemistry Staff, Bets on Biotech Drugs	Luke Timmerman	07/07/11	National
iPierian Shakeup Continues, as Chairman Corey Goodman, Scientist Doug Melton Exit Stem Cell Startup	Luke Timmerman	06/15/11	San Francisco
Termeer Joins Verastem Board	Luke Timmerman	06/13/11	Boston
At The Great Lakes Stem Cell (Innovation) Center, Researchers Anxiously Wait For Technology To Take Off	Thomas Lee	06/08/11	Detroit
Will Biotech Ever Again Captivate the Public Imagination, Like Facebook or LinkedIn?	Luke Timmerman	05/16/11	National
iPierian, Stem Cell Startup With Big Science & Big Bucks, Axes Group of Top Executives	Luke Timmerman	05/13/11	San Francisco
Takeda Bets on Fate Therapeutics	Luke Timmerman	05/10/11	San Diego
Geron Nabs $25M Loan from Stem Cell Agency, Paves Way for State Support of Clinical Trials	Luke Timmerman	05/05/11	San Francisco
StemCells Cuts 30% of Staff	Luke Timmerman	05/04/11	San Francisco
Q&A: UCSF’s Jeff Bluestone on the Tricky Balancing Act Between Academia and Industry	Luke Timmerman	03/10/11	San Francisco
Fate CEO Exits for New Co	Luke Timmerman	02/22/11	San Diego
Flagship VentureLabs, Creating and Spinning Out Cleantech and Life Sciences Startups for 10 Years, Takes the Veil Off	Erin Kutz	02/17/11	Boston
Fluidigm Completes IPO on 2nd Try, Geron CEO Exits, Amgen Pushes ‘Son of Dmab,’ & More Bay Area Life Sciences News	Luke Timmerman	02/11/11	San Francisco
Fluidigm Raises $75M in Second Chance at IPO	Luke Timmerman	02/10/11	San Francisco
Geron CEO Steps Down	Luke Timmerman	02/09/11	San Francisco
Axonia Seeks to Regenerate Nerves a New Way, Sidestepping Stem Cell Controversy	Luke Timmerman	01/25/11	Detroit
Page 1 of 5	next page »